60956-25-4

Usage

Uses

Used in Chemical Synthesis:
2-Bromo-1,3-dimethyl-4-nitrobenzene is used as an intermediate in the synthesis of more complex organic compounds. Its unique structure allows for further chemical reactions that can lead to the creation of a wide range of products.
Used in Pharmaceutical Industry:
In the pharmaceutical sector, 2-Bromo-1,3-dimethyl-4-nitrobenzene is used as a building block for the development of new drugs. Its chemical properties make it a valuable component in the synthesis of potential therapeutic agents.
Used in Dye Production:
2-Bromo-1,3-dimethyl-4-nitrobenzene is also utilized in the production of dyes. Its aromatic nature and functional groups contribute to the color properties of various dyes used in different industries.
It is important to handle 2-Bromo-1,3-dimethyl-4-nitrobenzene with care due to the potential risks associated with its bromine and nitro groups, which may require specific safety measures during its use in various applications.

Upstream product

• 67083-28-7 2,6-dimethyl-3-nitroaniline 
• 576-22-7 2-Bromo-m-xylene 

Downstream Products

• 610794-15-5 4-bromo-5-methyl-1H-indole 
• 66314-77-0 3-bromo-dimethylaniline 
• 69383-60-4 5-bromo-2,4-dimethylaniline 
• 693286-67-8 5-methylindole-4-boronic acid 
• 1063613-39-7 [2-(2-bromo-3-methyl-6-nitro-phenyl)-vinyl]-dimethyl-amine 
• 1449580-84-0 2-(5-methyl-1H-indol-4-yl)-5-[4-(3,3-dimethylpiperazin-1-yl)phenyl]-1,3-oxazole-4-carboxylic acid amide 
• 926922-44-3 6-methyl-2-N,N-dimethylaminomethyl-3-nitro-bromobenzene 
• 66314-79-2 3'-Brom-2,2-dichloro-2',4'-dimethylbenzoylacetanilid 
• 66314-78-1 3'-Brom-2',4'-dimethylbenzoylacetanilid 

Relevant academic research and scientific papers

AURORA AND FLT3 KINASES MODULATORS

The invention provides a compound having the formula (1): and salts thereof; wherein: R1 is hydrogen or C1-2 alkyl; and R2, R3 and R4 are the same or different and each is selected from hydrogen, C1-2 alkyl, fluorine, chlorine, C1-2 alkoxy and trifluoromethyl, provided that no more than two of R2, R3 and R4 are other than hydrogen. Also provided are pharmaceutical compositions containing the compounds and their use in medicine, and in particular in the treatment of cancer.

SERINE/THREONINE PAK1 INHIBITORS

Compounds having the formula I wherein A, Z, R1a, R1b, R2, R3, R4, R5, R6, R7, R9, R10, Ra, Rb and n are as defined herein are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.

AURORA AND FLT3 KINASES MODULATORS

The invention provides a compound having the formula (1) useful as modulator of the activity of Aurora kinases and FLT3 kinases: and salts thereof; wherein: R1 is hydrogen or C1-2 alkyl; and R2, R3 and R4 are the same or different and each is selected from hydrogen, C1-2 alkyl, fluorine, chlorine, C1-2 alkoxy and trifluoromethyl, provided that no more than two of R2, R3 and R4 are other than hydrogen. Also provided are pharmaceutical compositions containing the compounds and their use in medicine, and in particular in the treatment of cancer

THIOPHENE-2-CARBOXAMIDE DERIVATIVES AS MODULATORS OF CCR9 RECEPTOR

Provided are compounds of Formula (I) or of Formula (II) that are modulators of CCR9 receptor activity, compositions containing the compounds and methods of use of the compounds and compositions. In certain embodiments, provided are methods for treating or amelioratin diseases associated with modulation of CCR9 receptor activity.

INDOL-4-YL-PYRIMIDINYL-2-YL-AMINE DERIVATIVES AND USE THEREOF AS CYCLIN DEPENDANT KINASE INHIBITORS

The present application, describes organic compounds of formula I that are useful for the treatment, prevention and/or amelioration of cyclin dependent limase mediated diseases. (I)

Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitors

Novel N9-arenethenyl purines, optimized potent dual Src/Abl tyrosine kinase inhibitors, are described. The key structural feature is a trans vinyl linkage at N9 on the purine core which projects hydrophobic substituents into the sele

UNSATURATED HETEROCYCLIC DERIVATIVES

This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.

3-ARYL-5,6-DISUBSTITUTED PYRIDAZINES

The present invention provides compounds of Formula (I) or (II) salt form or prodrug thereof, wherein variables are defined herein, that are modulators of metalloproteases such as matrix metalloproteases (MMPs) and ADAMs. The compounds or compositions described herein can be used to treat diseases associated with metalloprotease activity including, for example, arthritis, cancer, cardiovascular disorders, skin disorders, inflammation or allergic conditions.

4,5-DISUBSTITUTED-2-ARYL PYRIMIDINES

4,5-disubstituted-2-arylpyrimidines of Formula (I) and Formula (II) are provided: wherein R1, R2, R3, R8, R9, A and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula I and II bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse activity at C5a receptors. The present invention also relates to pharmaceutical compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled 4,5-disubstituted-2-arylpyrimidines, which are useful as probes for the localization of C5a receptors.

1-ARYL-4-SUBSTITUTED ISOQUINOLINES

1-Aryl-4-substituted isoquinolines analogues of Formula (I) and Formula (II) are provided, as follows : wherein R1, R2, R3, R8, R9, A and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula (I) and (II) bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to pharmaceutical compositions compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled 1-aryl-4-substituted isoquinolines, which are useful as probes for the localization of C5a receptors.